MAPK3 and malignant colon neoplasm: We found that treatment with both baicalein and baicalin in HCT116 and SW480 colon cancer cells selectively activated ERK1/2 and p38, but not JNK, resulting in significantly enhanced phosphorylation of ERK1/2 and p38 in both colon cancer lines (Figure 6A and 6B, and data not shown).